2024 was an interesting year for pharmaceutical powerhouse Eli Lilly (NYSE ... outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had much to celebrate so ...

Eli Lilly (LLY ... over the past month versus the Zacks S&P 500 composite's -3.5% change. The Zacks Large Cap Pharmaceuticals industry, to which Lilly belongs, has lost 5.6% over this period.

Wall Street mostly rose Tuesday after encouraging inflation data despite Lilly’s drag. The post appeared first on TV News ...

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...

Most U.S. stocks rose following an encouraging update on inflation, but drops for Eli Lilly and some other influential stocks ...

Asian shares were mixed Tuesday, echoing trading on Wall Street, where gains for oil and gas producers helped offset drops ...

Is the stock market settling down after days of interest-rate-fueled selling hitting the Nasdaq Composite? Shortly after the ...

All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly ...

Drops for Eli Lilly and other influential companies are weighing on U.S. indexes Tuesday, even though most of the market is ...

Eli Lilly recently updated Q4 revenue guidance ... All told, Lilly stock still gained 33% in 2024, outperforming the S&P 500 and Nasdaq Composite. Unfortunately, Lilly investors haven't had ...